Investigator's Choice of Chemotherapy

Phase 3Small molecule

CCSPC Megalith Biopharmaceutical Co.,Ltd.

Investigator's Choice of Chemotherapy is one of 292 small molecule programs targeting Esophageal Squamous Cell Carcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

291

Competitors

Pipeline

Status by Indication[3][1]

Indication

Esophageal Squamous Cell CarcinomaActive, not recruiting

LymphomaActive, not recruiting

AdenocarcinomaActive, not recruiting

Triple-Negative Breast CancerActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Breast CancerActive, not recruiting

Ovarian CancerActive, not recruiting

Cervical CancerActive, not recruiting

Solid TumorRecruiting

Esophageal Squamous Cell CarcinomaPhase 3

Active, not recruiting

LymphomaPhase 3

Active, not recruiting

AdenocarcinomaPhase 3

Active, not recruiting

Triple-Negative Breast CancerPhase 3

Active, not recruiting

Non-Small Cell Lung CancerPhase 3

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

Ovarian CancerPhase 3

Active, not recruiting

Cervical CancerPhase 3

Active, not recruiting

Solid TumorPhase 3

Recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Investigator's Choice of Chemotherapy

CCSPC Megalith Biopharmaceutical Co.,Ltd.

Phase 3

3 2

Tecentriq

Roche

Preclinical

36 3

Trodelvy

Gilead

Preclinical

37 4

Halaven

Eisai

Preclinical

38 5

Tykerb

GSK

Preclinical

80 6

Adriamycin

GGynecologic Oncology Group

Preclinical

87 7

Avastin

BBio-Thera Solutions

Preclinical

153 8

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Preclinical

78 9

Prolia

Amgen

Preclinical

14 10

Gemzar

GGynecologic Oncology Group

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 3Recruiting

Triple-Negative Breast Cancer

NCT05954442

Q2 2027

Phase 3Recruiting

Adenocarcinoma

NCT07152405

Q3 2028

Phase 3Not yet recruiting

Cervical Cancer

NCT07230626

Q1 2029

Phase 3Recruiting

Solid Tumor

NCT07522073

Clinical

Trials by Indication[1]

Breast Cancer3 trials

A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer

Not yet recruiting·CCSPC Megalith Biopharmaceutical Co.,Ltd.·Phase 3·NCT07406542·400 enrolled

A Study to Evaluate the Efficacy and Safety of TSL-1502 Capsules in Breast Cancer Patients With Germline BRCA Mutations

Recruiting·UUnknown Sponsor·Phase 2·NCT05420779·125 enrolled

A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer

Completed· Roche logo

Roche·Phase 3·NCT05415215·346 enrolled

Esophageal Squamous Cell Carcinoma2 trials

SYS6010 Versus Chemotherapy in Locally Advanced or Metastatic/Recurrent Esophageal Squamous Cell Carcinoma

Not yet recruiting·CCSPC Megalith Biopharmaceutical Co.,Ltd.·Phase 3·NCT07417735·436 enrolled

QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Not yet recruiting· Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.·Phase 3·NCT07463573·466 enrolled

Cervical Cancer2 trials

SYS6002 vs Chemotherapy in Recurrent or Metastatic Cervical Cancer

Not yet recruiting·CCSPC Megalith Biopharmaceutical Co.,Ltd.·Phase 3·NCT07230626·412 enrolled

A Phase III Clinical Study of WX390 Combined With Toripalimab Versus Investigator's Choice of Therapy in Patients With Recurrent or Metastatic Cervical Cancer Who Have Failed Prior Platinum-Based Treatment

Not yet recruiting·SShanghai Jiatan Pharmatech Co., Ltd·Phase 3·NCT07392060·440 enrolled

Lymphoma2 trials

Study of Camrelizumab (SHR-1210) vs. Chemotherapy in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma

Unknown status·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT04342936·56 enrolled

A Phase III Study to Evaluate the Efficacy and Safety of Penpulimab in the Relapsed and Refractory Classical Hodgkin's Lymphoma

Recruiting·AAkeso·Phase 3·NCT05244642·60 enrolled

Ovarian Cancer2 trials

A Phase 3, Randomized, Open-Label Study of INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

Recruiting· Incyte logo

Incyte·Phase 3·NCT07214779·466 enrolled

A Randomized, Open-Label Phase 3 Study of Azenosertib Versus Investigator's Choice of Chemotherapy in Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression

Recruiting·KK-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.·Phase 3·NCT07546500·420 enrolled

5 more indications

Non-Small Cell Lung Cancer1 trial

LUX-Lung 5: Afatinib Plus Weekly Paclitaxel Versus Investigator's Choice of Single Agent Chemotherapy Following Afatinib Monotherapy in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT01085136·1,154 enrolled

Adenocarcinoma1 trial

A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-positive Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction Adenocarcinoma

Recruiting·SSichuan Baili Pharmaceutical Co., Ltd.·Phase 3·NCT07152405·490 enrolled

Advanced Solid Tumors1 trial

A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response

Completed· Roche logo

Roche·Phase 2·NCT04632992·252 enrolled

Triple-Negative Breast Cancer1 trial

Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) Subtype

Recruiting·FFudan University·Phase 3·NCT05954442·203 enrolled

Solid Tumor1 trial

A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)

Recruiting· Incyte logo

Incyte·Phase 3·NCT07522073·588 enrolled

Sources

References

[1]
ClinicalTrials.gov — 16 trial records for Investigator's Choice of Chemotherapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Investigator's Choice of Chemotherapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Investigator's Choice of Chemotherapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — CSPC Megalith Biopharmaceutical Co.,Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: CCSPC Megalith Biopharmaceutical Co.,Ltd.

Investigator's Choice of Chemotherapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q2 2027

Q3 2028

Q1 2029

Trials by Indication[1]

Breast Cancer3 trials

Esophageal Squamous Cell Carcinoma2 trials

Cervical Cancer2 trials

Lymphoma2 trials

Ovarian Cancer2 trials

Non-Small Cell Lung Cancer1 trial

Adenocarcinoma1 trial

Advanced Solid Tumors1 trial

Triple-Negative Breast Cancer1 trial

Solid Tumor1 trial

References

Drug Info

Quick Facts

Related News